



Allergan Aesthetics
an AbbVie company

A close-up portrait of a woman with dark hair pulled back, smiling broadly and looking upwards and to the right. Her skin is clear, bright, and appears hydrated. The background is a solid teal color with a faint white outline of a smiley face behind her.

Healthy-looking skin starts here


SKINVIVE™ by JUVÉDERM® is an injectable implant used for the treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity.¹

Disclaimer: From November 2025, SKINVIVE will replace VOLITE in Croatian market. SKINVIVE is the new rebranded name for Juvederm Volite. The product remains unchanged in its formulation and intended use; only the brand name and packaging have been updated.

FOR HEALTH CARE PROFESSIONALS ONLY
HR-SKV-250003 | HR-SKV-250003

Uncover an exciting opportunity in skin quality

Healthy-looking skin is more desired than ever.²⁻⁵ In fact, **~2 in 3 people** say having clear, glowing and healthy-looking skin helps them feel their best^{5,*} – and the demand for skin quality treatments is rising.^{4,5,*†}



This diagram shows multiple elements of skin quality. Adapted from Humphrey S *et al. Dermatol Surg.* 2021;47(7):974–981.

Skin health is an important factor when considering aesthetic treatment, as it can affect overall outcomes.⁷

Although patients have various options to improve skin quality, there's a big opportunity for a treatment that can provide long-lasting,[‡] deep[§] hydration^{||} in one session⁸

Meet SKINVIVE™

THE ONLY HYDRATING HA INJECTABLE LASTING
UP TO 9 MONTHS IN ONE TREATMENT^{8,9,11}

Developed with global skin health experts from the
world's #1 brand of hyaluronic acid facial fillers^{10,*}




Delivering
long-lasting,[‡]
deep[§] hydration,^{8,11}
SKINVIVE™ can
be the foundation
of a treatment plan
for patients
seeking healthy-
looking skin¹¹

Long-lasting,[‡] deep[§] hydration^{||} backed by science^{8,12}

LEVERAGE THE POWER OF HA AND BOOST LEVELS
OF AQP3^{12,††} FOR DEEP[§] SKIN HYDRATION^{8,||}



HA, the key ingredient in SKINVIVE™,¹ can attract and bind more than 1,000 times its weight in water.¹³



AQP3 is a key player in skin hydration¹⁴ and expression decreases with age, which may contribute to skin dryness.¹⁵



Adapted from Draelos Z. *J Clin Aesthet Dermatol.* 2012;5(7):53-56.

Hydration^{||} with SKINVIVE™ lasts for **up to 270 days⁸**
– unlike any other HA injectable on the market.^{9,†}

**Harness the power of SKINVIVE™ to give your patients
up to 9 months of deep[§] hydration^{||} in a single treatment⁸**



My skin feels a lot softer,
[...] more hydrated.

I feel more happy in myself, in my
skin. I just feel [...] more energised
when I look in the mirror and see
a fresh face looking at me.

“

ADAM, 33

This is the opinion of an individual patient and
has not been scripted by Allergan Aesthetics.
All patients received treatment with SKINVIVE™.
Adam received a total of 2 ml in the face.

Smooth.^{16,‡‡} Glowing.^{16,§§}
Healthy-looking.^{16,|||}
This is skin on
SKINVIVE™.

91%

of patients were **happier**
with their skin after
SKINVIVE™ treatment^{16,¶¶}

(At 1 month post-treatment [n=131])



All patients received treatment with SKINVIVE™.
Petra received a total of 2.5 mL in the face and 1 mL in the chest.

A seamless fit into your practice¹¹

FLEXIBILITY ACROSS DIFFERENT PATIENTS AND TREATMENT PLANS^{8,11,17}



Suitable for a diverse range of skin types^{8,17,* ** ,†††,‡‡‡}



Can be used alongside other aesthetic treatments^{11,§§§,|||||}

SKINVIVE™ should not be used simultaneously with laser treatment, deep chemical peels or dermabrasion. For surface peels, it is recommended not to inject the product if the inflammatory reaction generated is significant.¹

CONVENIENCE FOR YOU AND YOUR PATIENTS



After one treatment session, patients can enjoy results lasting up to 9 months⁸ with minimal downtime^{16,†††††}



Treatment typically takes between 8 and 15 minutes, making it convenient for both patients and practitioners^{18,* ** *}

For patients wanting to feel the benefits of improved skin quality attributes, choose SKINVIVE™^{6,8}

Patients may experience potential side effects with SKINVIVE™ by JUVÉDERM® facial filler, which include inflammatory reactions (redness, oedema, erythema, etc.), haematomas, induration or nodules, staining or discolourations at injection site, etc.
Please refer to SKINVIVE™ by JUVÉDERM® Directions for Use (DFU) for a full list of adverse events.

Adverse Events (AE) should be reported to local Regulatory Authority and EEMEA-MedDevicePQC@abbvie.com

Footnotes

- * Data from online interviews conducted between 14th July and 4th August 2021 of 12,360 “aesthetically aware” adults (aged 25–64 years) from Australia, Brazil, Canada, China, France, Germany, Japan, Italy, Russia, Spain, Taiwan, Thailand, Turkey, UAE and UK.⁵
- † Research conducted in August 2022 by Havas SO using Meltwater in English language only. Location: global. Timeframe: 5-year search (2017–2022). Sources: Digital and Print media coverage. Search terms: “Skin health, hyaluronic acid, injectable, injectables, injectable hydration treatments”⁴
- ‡ Long lasting is up to 9 months following a single treatment.⁸
- § Skin hydration was measured using the MoistureMeterD instrument with the XS 5 and S 15 probes (depth of effective measurement: 0.5 and 1.5 mm, respectively).⁸
- || Instrument measures of skin hydration, smoothness, and skin deformation parameters were performed on the cheek, forehead, and neck of one side of the face on Day 0 and at 30 days after initial treatment (before touch up), Months 1, 4, 6, and 9 after the last treatment, and Month 1R. Skin hydration was measured using the MoistureMeterD instrument (n=131) and top-up treatment administered at Day 30 (n=31).⁹
- ¶ Based on a search of published clinical studies of injectable HA treatments in March 2023. A duration of 9 months of skin hydration was established with SKINVIVE™.⁹
- ** Based on HCP tracking market research involving over 1,700 HCPs from 16 international markets.¹⁰
- †† Data derived from a prospective, non-randomised, interventional, open-label study where 11 healthy patients (men [n=2] and women [n=9]) received intradermal VYC-12L treatment on the volar forearm. Clinical probes assessed skin quality at baseline and Months 1 and 3 post-treatment. Punch biopsies were collected at Months 1 and 3 post-treatment to evaluate histologic and genomic changes.¹²
- ††† Lasting up to 9 months as reported by 55.1% of patients. As reported by patients (127/131) in a composite satisfaction score, which includes how smooth their facial skin looked.¹⁶
- §§ Lasting up to 9 months as reported by 63% of patients. As reported by patients (127/131) in a composite satisfaction score, which includes how radiant their facial skin looked.¹⁶
- ||| Lasting up to 9 months as reported by 76.2% of patients. As reported by patients (127/131; 1 subject did not respond) in a composite satisfaction score, which includes how healthy their facial skin looked.¹⁶
- ¶¶ Subjects completed the FACE-Q Satisfaction With Skin scale at baseline (Day 0, before treatment), Months 1, 4, 6, and 9 (before repeat treatment, if received), and Month 1 after the repeat treatment (n=131; n=62 received repeat treatment). The Satisfaction With Skin scale is a validated patient-reported outcome instrument designed to assess the impact of treatment from the subject’s perspective. The scale comprises 12 questions about satisfaction with different facial skin attributes (e.g., smoothness, clearness, radiance). Responses are rated on a 4-point scale (1: very dissatisfied, 4: very satisfied). Scores for each item were summed and converted to a scale score (range: 0–100; higher scores indicate greater satisfaction) using the algorithm developed by the FACE-Q developers.¹⁶
- *** The Fitzpatrick classification denotes six different skin types, skin colour and reaction to sun exposure (type I: burns easily, never tans; type II: burns easily, tans minimally with difficulty; type III: burns moderately, tans moderately and uniformly; type IV: burns minimally, tans moderately and easily; type V: rarely burns, tans profusely; type VI: never burns, tans profusely).¹³
- †††† Data from a randomised, evaluator-blind, delayed control study in which 209 patients with moderate/severe Allergan Cheek Smoothness Scale scores were randomised to receive VYC-12L via intradermal microdepot injections to both cheeks (n=136) or control (no treatment with optional treatment) (n=73). The majority of patients had Fitzpatrick skin types III/IV (58.8%), followed by I/II (32.0%) and V/VI (9.2%). Effectiveness measures included changes in cheek skin smoothness, changes in cheek fine lines and skin hydration at Months 1, 2, 4 and 6 after the final injection (initial or touch-up).¹⁷
- ††††† Data from a prospective, single-arm study in which 131 patients with moderate/severe cheek skin roughness as per Allergan Skin Roughness Scale received VYC-12 intradermally in the cheeks and forehead, with an option to treat the neck. Select patients (n=31) received touch-up treatment 30 days after initial treatment to correct asymmetry. The majority of patients had Fitzpatrick skin type III (53.4%), followed by II (35.1%), IV (10.7%) and V (0.8%). Assessments of cheek skin roughness, cheek fine lines and skin hydration were performed at 30 days after initial treatment (before touch-up), Months 1, 4, 6 and 9 after last treatment (initial or touch-up) and 1 month after repeat treatment.³
- §§§ SKINVIVE™ must not be used in: patients suffering from untreated epilepsy; patients who tend to develop hypertrophic scarring; patients with known hypersensitivity to hyaluronic acid and/or to gram positive bacterial proteins as hyaluronic acid is produced by *Streptococcus* type bacteria; patients with known hypersensitivity to lidocaine or to amide-type local anaesthetics; patients suffering from porphyria; women who are pregnant or breastfeeding; children. SKINVIVE™ must not be used in areas presenting cutaneous inflammatory and/or infectious processes (acne, herpes etc.).¹
- |||| Data from a retrospective case review undertaken at a single cosmetic dermatology clinic in Vancouver, Canada. A total of 736 patients treated with a total of 1577 VYC-12 treatments were identified; for each VYC-12 treatment, other modalities used on the same day or in the subsequent 9 months were recorded. 718 patients received same-day or asynchronous combination treatments, and 1444 VYC-12 treatments were performed with same-day combination treatments. Data captured included VYC-12 volumes, time interval between treatments, patient age, gender, and adverse events.¹¹
- ¶¶¶ In a prospective, single-arm study of 131 patients, subjects assessed their return to normal daily social activities (yes/no) in diaries on Days 1, 2 and 3 after each treatment.¹⁶
- **** Based on a survey done with 6 healthcare professional experts in skin quality treatments regarding their clinical experience with injection time in the area of the face.¹⁸

Abbreviations

AQP3, aquaporin-3; HA, hyaluronic acid.

References

1. SKINVIVE by Juvederm DFU 2. Allergan Aesthetics. Data on file. ALL-AGNA-220122. The Future of Aesthetics Global Trends Report. July 2022. 3. Beauty Independent. Forget Beauty. These Days, Skincare Is All About Health. But What Exactly Is Skin Health? Available at: <https://www.beautyindependent.com/skincare-what-exactly-skin-health/> [Accessed November 2023]. 4. Allergan Aesthetics. Data on file. REF-100241. Skin Health Media Statistics. August 2022. 5. Allergan Aesthetics. Data on file. Consumer Beauty Insights Survey 2021. August 2021. 6. Humphrey S et al. *Dermatol Surg*. 2021;47(7):974–981. 7. Varga R. *J Aesthet Nurs*. 2022;11(5):206–212. 8. Niforos F et al. *Clin Cosmet Investig Dermatol*. 2019;12:791–798. 9. Allergan Aesthetics. Unpublished data. SKINVIVE™ by JUVÉDERM® – 9-month duration of skin hydration in clinical trials. March 2023. 10. Allergan Aesthetics. Unpublished data. JUVÉDERM®, the world’s leading brand of hyaluronic acid facial fillers. REF-108642. March 2023. 11. Zarfavian M et al. *Dermatol Surg*. 2022;48(3):369–372. 12. Safa M et al. *Clin Cosmet Investig Dermatol*. 2022;15:411–426. 13. Nakab L et al. *Plast Reconstr Surg Glob Open*. 2020;8(3):e2723. 14. Bollag W et al. *Am J Physiol Cell Physiol*. 2020;318(6):C1144–C1153. 15. Draelos Z. *J Clin Aesthet Dermatol*. 2012;5(7):53–56. 16. Ogilvie P et al. *J Cosmet Dermatol*. 2020;19(5):1065–1070. 17. Alexiades M et al. *Dermatol Surg*. 2023;49(7):682–688. 18. Allergan Aesthetics. Unpublished data. SKINVIVE™ time of injection. REF-116636. October 2023. 19. Sachdeva S. *Indian J Dermatol Venereol Leprol*. 2009;75(1):93–96.



Allergan Aesthetics
an AbbVie company